BerGenBio

Selective AXL inhibitors

Home  /  Media Centre  /  Presentations

EHA 24, Loges at al

Share This Presentation

June 13 – 16 2019, Amsterdam, Netherlands

Poster Presentation:
The Combination of bemcentinib, a novel, oral, selective AXL-Inhibitor and Low-Dose Cytarabine yields Durable Responses in AML patients Unfit for Intensive Chemotherapy

Share This Presentation

Latest News

News

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

News

BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.